0

Close
 
Upcoming Allied Market Research
2023
Cardiac Arrest Treatment Market

Cardiac Arrest Treatment Market: Global Opportunity Analysis and Industry Forecast, 2023-2030 Market

LS : Pharmaceuticals
Report Code: A08079
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cardiac Arrest Treatment Market

Request Now !

Cardiac arrest is a serious medical condition wherein there is abrupt loss of heart function, breathing and consciousness. The condition usually results from an electrical disturbance in the heart that disrupts its pumping action, stopping blood flow to body. This occurs when the demand for oxygen towards heart isn’t sufficient and forces the mortality of heart muscles cells causing a heart attack. Sudden cardiac arrest often occurs with no warning and if not treated immediately, can lead to brain damage and death. There are numerous other reasons causing cardiac arrest like coronary heart disease, cardiomyopathy, some inherited heart conditions, congenital heart disease, heart valve disease, acute myocarditis, Brugada syndrome, long QT syndrome, Diabetes and even excessive drinking and lethargic lifestyle. Among these, the coronary artery disease is the most common cause for sudden cardiac arrest especially among people belonging to 35 years and above age group. The Brugada syndrome and long QT syndrome initiates abnormal heart rate which facilitates a cardiac arrest problem while the cardiomyopathy situation causes heart muscle to develop to abnormal size and causes cardiac arrest problems.

COVID-19 scenario analysis: 

  • Due to the COVID – 19  outbreak, majority of healthcare, pharmaceutical and biotechnology organizations have concentrated on diagnostics kits, safety wearables (PPE kits, face shields, masks) and treatment therapies and medication against Novel coronavirus
  • R&D labs are also focusing on finding a breakthrough vaccine against Novel coronavirus
  • In addition, the medical professionals are engaged in providing COVID-19 related services, unavailability if experts to treat patients suffering from cardiac arrests
  • As a result, other healthcare segments  have to face negligence
  • In addition, it has been observed after some research that people with prevalence of cardiac diseases are at higher risk for mortality and morbidity related to COVID-19 compared to the average population 
  • Recent studies have also revealed that COVID-19 can cause heart injury, even in people without heart abnormalities
  • Henceforth, patients and the cardiac arrest treatment industry is facing struggles amid COVID-19 pandemic
  • However, the demand for CPR devices amidst COVID-19 pandemic is soaring in order to reduce the risk of myocardial injury, acute respiratory disease, and ventricular arrhythmias which leads to an increase in the risk of cardiac arrest
  • COVID-19 can cause these conditions and  to minimize their risk healthcare professionals are using cardiopulmonary resuscitation (CPR) devices, thus their demand is rising

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Rise in cardiovascular diseases, changing lethargic and sedentary lifestyle with desk-bound jobs, increase in the geriatric population and investments in R&D activities related to cardiac diseases are the major driving forces in cardiac arrest treatment market growth. As per the Global Health and Wellness Report published in 2018, in United States approximately 40% of the adult population were diagnosed with a cardiovascular condition which resulted in higher demand for advanced and efficient treatment and upgraded cardiovascular devices to treat the patients fostering the growth of the market throughout.

Investments in R&D activities cardiac arrest treatment is expected to foster the market growth. In March 2017, researchers from the University of Copenhagen concluded that Ibuprofen should not be sold as an OTC (over the counter) drug as it increases the risk of cardiac arrest by 31%. Report published in September 2019 in Nature, researchers from University of Pennsylvania's Abramson Cancer Center used CAR-T cells to treat cardiac fibrosis, disease associated with cardiac arrest. They also explained how the T cell therapy ultimately leads to heart failure. In June 2019, a group of researchers at British Heart Foundation developed a blood test that identifies heart failure prior and a pumping mechanism that could aid in repairing heart damage after cardiac arrest. The increasing number of research activities thus are driving the market. On the contrary, the lack of availability of the healthcare professionals in the developing and under-developed economies and the stringent guideline issued by regulatory authorities are hampering the growth of cardiac arrest treatment market.

Increase in prevalence of cardiac diseases

Cardiovascular diseases hold the first place in cause for death globally than any other disease according to World Health Organization (WHO). In 2016, cardiac diseases caused fatality in an estimated 17.9 million people, highlighting 31% of all global deaths with majority deaths were accounted in developing economies with low- and middle- income category. This can be an opportunity to the cardiac arrest treatment to expand into developing economies.

Cardiac diseases are increasing with rising population and changing lifestyle. According to the Centers for Disease Control, the number of deaths due to cardiac diseases in United States is more than 606,000 on yearly basis. Four out of five CVD deaths are due to heart attacks and strokes. According to the World Journal of Cardiovascular Diseases, more than 7 million deaths are due to the sudden cardiac arrest worldwide every year. This makes the cardiac arrest treatment essential in diagnosis and treatment of cardiac disorders. Thus, the growing cases of heart failures, heart attacks, strokes, and other heart-related conditions are facilitating the cardiac arrest treatment market growth. 

Sedentary lifestyle and obesity expected to fuel growth

The sedentary lifestyle is further expected to surge the market. According to World Health Organization (WHO), sedentary lifestyles proves to be fatal for around 5.3 million people every year globally, with minimum 300,000 premature deaths and US$90 billion are spent in directly as healthcare costs to reduce problems caused by obesity and sedentary lifestyle yearly in the U.S. Physical inactivity causes around 2 million deaths every year forcing WHO to issue a warning regarding sedentary lifestyle being among top ten major causes of death and disability around the world. The US Department of Health and Human Service, stated only one in three children are physically active every day in the U.S. Thus, the rising sedentary lifestyle would cause cardiac problems creating opportunities for cardiac arrest market growth.

World Health Organization (WHO) in their report, mentioned the rate of obesity has tripled since 1975 worldwide. In 2016, over 1.9 billion adults belonging to age group 18 years or above were overweight and out of them, over one third of people were obese. These factors increase the risk of cardiovascular diseases significantly and eventually increase the chances of having a cardiac arrest. As a result, problems arising due to obesity would create growth pockets for cardiac arrest treatment market.

Key benefits of the report:

  • This study presents the analytical depiction of the global cardiac arrest treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global cardiac arrest treatment market share.
  • The current market is quantitatively analysed to highlight the global cardiac arrest treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed global cardiac arrest treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Cardiac Arrest Treatment Market research report:

  • Who are the leading market players active in the cardiac arrest treatment market?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the market?
  • What are the projections for the future that will help in taking further strategic steps?

 Cardiac Arrest Treatment Market: Global Opportunity Analysis and Industry Forecast, 2020-2027 Report Highlights

Aspects Details
By Drugs
  • Vasopressors
  • Anti-arrhythmic Drugs
  • Anticholinergic Drugs
  • Corticosteroids
  • Fibrinolytic Drugs
  • Beta Blockers
  • Others
By Medical devices
  • Defibrillators
  • Cardiac Resynchronization Therapy (CRT)
  • Others
By Distribution channels
  • Hospitals
  • Retail pharmacies
  • Online pharmacies
  • Others
By Region
  • North America  (US, Canada, Mexico)
  • Europe  (France, Germany, UK, Italy, Spain, rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, South Korea, rest of Asia-Pacific)
  • LAMEA  (Brazil, South Arabia, South Africa, rest of LAMEA)
Key Market Players Koninklijke Philips N.V, Novartis AG, Bayer AG, GE Healthcare, Pfizer Inc, Abbott, Amgen Inc, Boston Scientific Corporation., Stryker, Bristol-Myers Squibb Company
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: CARDIAC ARREST TREATMENT MARKET, BY DRUGS

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Drugs

    • 4.2. Vasopressors

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Anti-arrhythmic Drugs

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Anticholinergic Drugs

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Corticosteroids

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Fibrinolytic Drugs

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Beta Blockers

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

    • 4.8. Others

      • 4.8.1. Key Market Trends, Growth Factors and Opportunities

      • 4.8.2. Market Size and Forecast, By Region

      • 4.8.3. Market Share Analysis, By Country

  • CHAPTER 5: CARDIAC ARREST TREATMENT MARKET, BY MEDICAL DEVICES

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Medical Devices

    • 5.2. Defibrillators

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Cardiac Resynchronization Therapy (CRT)

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: CARDIAC ARREST TREATMENT MARKET, BY DISTRIBUTION CHANNELS

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channels

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Retail Pharmacies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Online Pharmacies

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Others

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

  • CHAPTER 7: CARDIAC ARREST TREATMENT MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Drugs

      • 7.2.3. Market Size and Forecast, By Medical Devices

      • 7.2.4. Market Size and Forecast, By Distribution Channels

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S. Cardiac Arrest Treatment Market

        • 7.2.6.1. Market Size and Forecast, By Drugs
        • 7.2.6.2. Market Size and Forecast, By Medical Devices
        • 7.2.6.3. Market Size and Forecast, By Distribution Channels

      • 7.2.7. Canada Cardiac Arrest Treatment Market

        • 7.2.7.1. Market Size and Forecast, By Drugs
        • 7.2.7.2. Market Size and Forecast, By Medical Devices
        • 7.2.7.3. Market Size and Forecast, By Distribution Channels

      • 7.2.8. Mexico Cardiac Arrest Treatment Market

        • 7.2.8.1. Market Size and Forecast, By Drugs
        • 7.2.8.2. Market Size and Forecast, By Medical Devices
        • 7.2.8.3. Market Size and Forecast, By Distribution Channels

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Drugs

      • 7.3.3. Market Size and Forecast, By Medical Devices

      • 7.3.4. Market Size and Forecast, By Distribution Channels

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France Cardiac Arrest Treatment Market

        • 7.3.6.1. Market Size and Forecast, By Drugs
        • 7.3.6.2. Market Size and Forecast, By Medical Devices
        • 7.3.6.3. Market Size and Forecast, By Distribution Channels

      • 7.3.7. Germany Cardiac Arrest Treatment Market

        • 7.3.7.1. Market Size and Forecast, By Drugs
        • 7.3.7.2. Market Size and Forecast, By Medical Devices
        • 7.3.7.3. Market Size and Forecast, By Distribution Channels

      • 7.3.8. Italy Cardiac Arrest Treatment Market

        • 7.3.8.1. Market Size and Forecast, By Drugs
        • 7.3.8.2. Market Size and Forecast, By Medical Devices
        • 7.3.8.3. Market Size and Forecast, By Distribution Channels

      • 7.3.9. Spain Cardiac Arrest Treatment Market

        • 7.3.9.1. Market Size and Forecast, By Drugs
        • 7.3.9.2. Market Size and Forecast, By Medical Devices
        • 7.3.9.3. Market Size and Forecast, By Distribution Channels

      • 7.3.10. UK Cardiac Arrest Treatment Market

        • 7.3.10.1. Market Size and Forecast, By Drugs
        • 7.3.10.2. Market Size and Forecast, By Medical Devices
        • 7.3.10.3. Market Size and Forecast, By Distribution Channels

      • 7.3.11. Russia Cardiac Arrest Treatment Market

        • 7.3.11.1. Market Size and Forecast, By Drugs
        • 7.3.11.2. Market Size and Forecast, By Medical Devices
        • 7.3.11.3. Market Size and Forecast, By Distribution Channels

      • 7.3.12. Rest Of Europe Cardiac Arrest Treatment Market

        • 7.3.12.1. Market Size and Forecast, By Drugs
        • 7.3.12.2. Market Size and Forecast, By Medical Devices
        • 7.3.12.3. Market Size and Forecast, By Distribution Channels

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Drugs

      • 7.4.3. Market Size and Forecast, By Medical Devices

      • 7.4.4. Market Size and Forecast, By Distribution Channels

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China Cardiac Arrest Treatment Market

        • 7.4.6.1. Market Size and Forecast, By Drugs
        • 7.4.6.2. Market Size and Forecast, By Medical Devices
        • 7.4.6.3. Market Size and Forecast, By Distribution Channels

      • 7.4.7. Japan Cardiac Arrest Treatment Market

        • 7.4.7.1. Market Size and Forecast, By Drugs
        • 7.4.7.2. Market Size and Forecast, By Medical Devices
        • 7.4.7.3. Market Size and Forecast, By Distribution Channels

      • 7.4.8. India Cardiac Arrest Treatment Market

        • 7.4.8.1. Market Size and Forecast, By Drugs
        • 7.4.8.2. Market Size and Forecast, By Medical Devices
        • 7.4.8.3. Market Size and Forecast, By Distribution Channels

      • 7.4.9. South Korea Cardiac Arrest Treatment Market

        • 7.4.9.1. Market Size and Forecast, By Drugs
        • 7.4.9.2. Market Size and Forecast, By Medical Devices
        • 7.4.9.3. Market Size and Forecast, By Distribution Channels

      • 7.4.10. Australia Cardiac Arrest Treatment Market

        • 7.4.10.1. Market Size and Forecast, By Drugs
        • 7.4.10.2. Market Size and Forecast, By Medical Devices
        • 7.4.10.3. Market Size and Forecast, By Distribution Channels

      • 7.4.11. Thailand Cardiac Arrest Treatment Market

        • 7.4.11.1. Market Size and Forecast, By Drugs
        • 7.4.11.2. Market Size and Forecast, By Medical Devices
        • 7.4.11.3. Market Size and Forecast, By Distribution Channels

      • 7.4.12. Malaysia Cardiac Arrest Treatment Market

        • 7.4.12.1. Market Size and Forecast, By Drugs
        • 7.4.12.2. Market Size and Forecast, By Medical Devices
        • 7.4.12.3. Market Size and Forecast, By Distribution Channels

      • 7.4.13. Indonesia Cardiac Arrest Treatment Market

        • 7.4.13.1. Market Size and Forecast, By Drugs
        • 7.4.13.2. Market Size and Forecast, By Medical Devices
        • 7.4.13.3. Market Size and Forecast, By Distribution Channels

      • 7.4.14. Rest of Asia Pacific Cardiac Arrest Treatment Market

        • 7.4.14.1. Market Size and Forecast, By Drugs
        • 7.4.14.2. Market Size and Forecast, By Medical Devices
        • 7.4.14.3. Market Size and Forecast, By Distribution Channels

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Drugs

      • 7.5.3. Market Size and Forecast, By Medical Devices

      • 7.5.4. Market Size and Forecast, By Distribution Channels

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil Cardiac Arrest Treatment Market

        • 7.5.6.1. Market Size and Forecast, By Drugs
        • 7.5.6.2. Market Size and Forecast, By Medical Devices
        • 7.5.6.3. Market Size and Forecast, By Distribution Channels

      • 7.5.7. South Africa Cardiac Arrest Treatment Market

        • 7.5.7.1. Market Size and Forecast, By Drugs
        • 7.5.7.2. Market Size and Forecast, By Medical Devices
        • 7.5.7.3. Market Size and Forecast, By Distribution Channels

      • 7.5.8. Saudi Arabia Cardiac Arrest Treatment Market

        • 7.5.8.1. Market Size and Forecast, By Drugs
        • 7.5.8.2. Market Size and Forecast, By Medical Devices
        • 7.5.8.3. Market Size and Forecast, By Distribution Channels

      • 7.5.9. UAE Cardiac Arrest Treatment Market

        • 7.5.9.1. Market Size and Forecast, By Drugs
        • 7.5.9.2. Market Size and Forecast, By Medical Devices
        • 7.5.9.3. Market Size and Forecast, By Distribution Channels

      • 7.5.10. Argentina Cardiac Arrest Treatment Market

        • 7.5.10.1. Market Size and Forecast, By Drugs
        • 7.5.10.2. Market Size and Forecast, By Medical Devices
        • 7.5.10.3. Market Size and Forecast, By Distribution Channels

      • 7.5.11. Rest of LAMEA Cardiac Arrest Treatment Market

        • 7.5.11.1. Market Size and Forecast, By Drugs
        • 7.5.11.2. Market Size and Forecast, By Medical Devices
        • 7.5.11.3. Market Size and Forecast, By Distribution Channels

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. GE Healthcare

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Novartis AG

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Pfizer Inc

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Amgen Inc

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Abbott

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Bristol-Myers Squibb Company

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Koninklijke Philips N.V

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Bayer AG

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Stryker

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Boston Scientific Corporation.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CARDIAC ARREST TREATMENT MARKET, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR VASOPRESSORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR ANTI-ARRHYTHMIC DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR ANTICHOLINERGIC DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR CORTICOSTEROIDS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR FIBRINOLYTIC DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR BETA BLOCKERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. GLOBAL CARDIAC ARREST TREATMENT MARKET, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 10. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR DEFIBRILLATORS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY (CRT), BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL CARDIAC ARREST TREATMENT MARKET, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. GLOBAL CARDIAC ARREST TREATMENT MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. GLOBAL CARDIAC ARREST TREATMENT MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA CARDIAC ARREST TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 23. U.S. CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 24. U.S. CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 25. U.S. CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 26. CANADA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 27. CANADA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 28. CANADA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE CARDIAC ARREST TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 42. ITALY CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 43. ITALY CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 44. ITALY CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 48. UK CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 49. UK CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 50. UK CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 52. RUSSIA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 53. RUSSIA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC CARDIAC ARREST TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 61. CHINA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 62. CHINA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 63. CHINA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 65. JAPAN CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 67. INDIA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 68. INDIA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 69. INDIA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 77. THAILAND CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 78. THAILAND CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 80. MALAYSIA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 81. MALAYSIA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 83. INDONESIA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 84. INDONESIA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA CARDIAC ARREST TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 93. BRAZIL CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 94. BRAZIL CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 101. UAE CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 102. UAE CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 103. UAE CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 105. ARGENTINA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 106. ARGENTINA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA CARDIAC ARREST TREATMENT, BY DRUGS, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA CARDIAC ARREST TREATMENT, BY MEDICAL DEVICES, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA CARDIAC ARREST TREATMENT, BY DISTRIBUTION CHANNELS, 2022-2032 ($MILLION)
  • TABLE 110. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 111. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 112. GE HEALTHCARE: OPERATING SEGMENTS
  • TABLE 113. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 114. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 116. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 117. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 118. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 119. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. PFIZER INC: KEY EXECUTIVES
  • TABLE 121. PFIZER INC: COMPANY SNAPSHOT
  • TABLE 122. PFIZER INC: OPERATING SEGMENTS
  • TABLE 123. PFIZER INC: PRODUCT PORTFOLIO
  • TABLE 124. PFIZER INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. AMGEN INC: KEY EXECUTIVES
  • TABLE 126. AMGEN INC: COMPANY SNAPSHOT
  • TABLE 127. AMGEN INC: OPERATING SEGMENTS
  • TABLE 128. AMGEN INC: PRODUCT PORTFOLIO
  • TABLE 129. AMGEN INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. ABBOTT: KEY EXECUTIVES
  • TABLE 131. ABBOTT: COMPANY SNAPSHOT
  • TABLE 132. ABBOTT: OPERATING SEGMENTS
  • TABLE 133. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 134. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 136. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 137. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 138. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 139. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. KONINKLIJKE PHILIPS N.V: KEY EXECUTIVES
  • TABLE 141. KONINKLIJKE PHILIPS N.V: COMPANY SNAPSHOT
  • TABLE 142. KONINKLIJKE PHILIPS N.V: OPERATING SEGMENTS
  • TABLE 143. KONINKLIJKE PHILIPS N.V: PRODUCT PORTFOLIO
  • TABLE 144. KONINKLIJKE PHILIPS N.V: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. BAYER AG: KEY EXECUTIVES
  • TABLE 146. BAYER AG: COMPANY SNAPSHOT
  • TABLE 147. BAYER AG: OPERATING SEGMENTS
  • TABLE 148. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 149. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. STRYKER: KEY EXECUTIVES
  • TABLE 151. STRYKER: COMPANY SNAPSHOT
  • TABLE 152. STRYKER: OPERATING SEGMENTS
  • TABLE 153. STRYKER: PRODUCT PORTFOLIO
  • TABLE 154. STRYKER: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. BOSTON SCIENTIFIC CORPORATION.: KEY EXECUTIVES
  • TABLE 156. BOSTON SCIENTIFIC CORPORATION.: COMPANY SNAPSHOT
  • TABLE 157. BOSTON SCIENTIFIC CORPORATION.: OPERATING SEGMENTS
  • TABLE 158. BOSTON SCIENTIFIC CORPORATION.: PRODUCT PORTFOLIO
  • TABLE 159. BOSTON SCIENTIFIC CORPORATION.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CARDIAC ARREST TREATMENT MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CARDIAC ARREST TREATMENT MARKET
  • FIGURE 3. SEGMENTATION CARDIAC ARREST TREATMENT MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CARDIAC ARREST TREATMENT MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCARDIAC ARREST TREATMENT MARKET
  • FIGURE 11. CARDIAC ARREST TREATMENT MARKET SEGMENTATION, BY BY DRUGS
  • FIGURE 12. CARDIAC ARREST TREATMENT MARKET FOR VASOPRESSORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CARDIAC ARREST TREATMENT MARKET FOR ANTI-ARRHYTHMIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CARDIAC ARREST TREATMENT MARKET FOR ANTICHOLINERGIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CARDIAC ARREST TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. CARDIAC ARREST TREATMENT MARKET FOR FIBRINOLYTIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CARDIAC ARREST TREATMENT MARKET FOR BETA BLOCKERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CARDIAC ARREST TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. CARDIAC ARREST TREATMENT MARKET SEGMENTATION, BY BY MEDICAL DEVICES
  • FIGURE 20. CARDIAC ARREST TREATMENT MARKET FOR DEFIBRILLATORS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. CARDIAC ARREST TREATMENT MARKET FOR CARDIAC RESYNCHRONIZATION THERAPY (CRT), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. CARDIAC ARREST TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. CARDIAC ARREST TREATMENT MARKET SEGMENTATION, BY BY DISTRIBUTION CHANNELS
  • FIGURE 24. CARDIAC ARREST TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. CARDIAC ARREST TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. CARDIAC ARREST TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. CARDIAC ARREST TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 32. COMPETITIVE DASHBOARD
  • FIGURE 33. COMPETITIVE HEATMAP: CARDIAC ARREST TREATMENT MARKET
  • FIGURE 34. Top player positioning, 2022
  • FIGURE 35. GE HEALTHCARE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. GE HEALTHCARE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. PFIZER INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. PFIZER INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. PFIZER INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. AMGEN INC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. AMGEN INC: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. AMGEN INC: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. KONINKLIJKE PHILIPS N.V: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. KONINKLIJKE PHILIPS N.V: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. KONINKLIJKE PHILIPS N.V: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BAYER AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. BAYER AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. STRYKER: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. STRYKER: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. STRYKER: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. BOSTON SCIENTIFIC CORPORATION.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. BOSTON SCIENTIFIC CORPORATION.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. BOSTON SCIENTIFIC CORPORATION.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Cardiac Arrest Treatment Market

Start reading.
This Report and over 66,966+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers